IBD-0333

Main study objectives Dose escalation phase: Evaluate the safety and tolerability of IBD0333 in subjects with locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma, and determine the maximum tolerated dose (MTD), recommended dose for expansion (DRDE) and/or dose-limiting toxicity (DLT). Dose expansion phase: Evaluate the safety and tolerability of IBD0333 in subjects with locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma, and determine the recommended dose for Phase II clinical studies (RP2D). Clinical exploration phase: Evaluate the preliminary efficacy of IBD0333 in subjects with specific tumor types. Secondary study objectives Dose escalation phase & dose expansion phase: Evaluate the pharmacokinetic (PK) characteristics of IBD0333 in subjects with locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma; Evaluate the immunogenicity of IBD0333 in subjects with locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma; Evaluate the preliminary efficacy of IBD0333 in subjects with locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma. Clinical Exploration Phase: Evaluate the safety and tolerability of IBD0333 in subjects with specific tumor types; Evaluate the immunogenicity of IBD0333 in subjects with specific tumor types. Purpose of Exploratory Research Explore biomarkers in blood and tissues that predict the potential efficacy of IBD0333.